Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for... However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
- Mechanism
- Curator reviewed
Dexfenfluramine binds to the serotonin reuptake pump. This causes inhbition of serotonin reuptake. The increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates.
- Primary indication
- For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie dietCurator reviewed
- Formula / weight
- C12H16F3N · 231.2573 g/mol (avg)
- Also known as
- (S)-fenfluramine · Dextrofenfluramine
- Code names
- J13.711A · S 5614
Resolves to
DBGIVFWFUFKIQN-VIFPVBQESA-NSMILESCCN[C@@H](C)CC1=CC=CC(=C1)C(F)(F)FWhat you can answer from here — as of September 11, 2026
Which drugs share a target with Dexfenfluramine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account